At the heart of Europe's financial centres, our London- and Frankfurt-based European Corporate practice advises on domestic, multi-jurisdictional, and cross-border corporate transactions. Our experience includes a focus on private equity, mergers and acquisitions, and life sciences transactions.
Our principle areas of focus include:
- Advising corporations on European and cross-border M&A transactions, joint ventures, and reorganizations.
- Advising on both venture capital for growth companies and private equity transactions, representing funds and other investors, and their portfolio companies and management teams.
- Advising on equity issues and on debt issues particularly for sovereigns in the international capital markets.
- Advising on corporate governance procedures and developments.
We act for a large number of organisations in highly regulated industries, such as financial services, biotechnology, fast-moving consumer goods, chemicals, pharmaceuticals, biologicals, healthcare, and medical devices. Our additional sector focus includes retail, for profit education, and real estate investments.
What sets us apart from other firms is our multidisciplinary approach to handling transactions—the breadth of our regulatory practices complements our transactions experience, providing a strategic advantage to our clients. We also work closely with our tax, employment, intellectual property, competition, and finance experts to provide all-round support.
Represented Armour Home Electronics Limited in the disposal of its office furniture business to Dorel Home.
Represented leading independent global marketing activation partner in its acquisition of a leading digital production studio.
Represented Equine Clinic Grosswallstadt on its sale to Altano Gruppe GmbH (Altano), a portfolio company of Ufenau Capital Partners.
Advised Maryland-based publicly traded REIT on its $133 million acquisition and lease-back transaction concerning 18 care home facilities in the UK with Gold Care Holdings Limited.
Advised this Maryland-based publicly traded REIT on a new $1.8 billion senior unsecured revolving and term loan credit facility, an amended and restated $250 million senior unsecured term loan credit facility and, for its subsidiary, a new $100 million senior unsecured term loan credit facility.